The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects

Opioid Dependence Clinical Trial

Official title:

A Randomized, Double-blind, Active Control Evaluation of the Safety of BioErodible MucoAdhesive (BEMA®) Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02516436
• Other study ID #: BNX-302
• Status: Withdrawn
• Phase: Phase 3
• First received: August 3, 2015
• Last updated: May 2, 2017
• Est. completion date: May 1, 2017

Study information

• Verified date: May 2017
• Source: BioDelivery Sciences International
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double blind, active controlled study in approximately 40 opioid dependent subjects. Study duration is up to five days and includes a maximum of 3 days confinement in the clinic. Opioid dependent subjects who provide informed consent meet all entry criteria are eligible for enrollment into the study.

Description:

A randomized, double blind, active controlled study in approximately 40 opioid dependent subjects. The study includes a Screening period of up to 3 days and a 2-day, double blind induction phase (subjects confined to the clinic). Screening and the first day of treatment (Day 1) may occur on the same day or Screening may occur up to 3 days prior to Day 1.

Opioid dependent subjects who provide informed consent at the Screening visit; have a Clinical Opiate Withdrawal Scale (COWS) total score ≥12; and meet other entry criteria are eligible for enrollment into the study. Subjects will be confined to the clinic beginning on Day 1 (optional confinement on Day -1) and will remain there for up to 48 hours after administration of the first study drug dose.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 1, 2017
• Est. primary completion date: May 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent obtained prior to any study procedure being performed

2. Pre-specified plan for continued treatment following study participation

3. Male or non-pregnant and non-nursing female. A female of childbearing potential is eligible to participate in this study if she is not pregnant and is using an acceptable method of birth control.

4. Subject is aged 18 to 55 years, inclusive

5. Current diagnosis of opioid substance use disorder per the Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5)

6. Clinical opioid withdrawal scale (COWS) total score =12 prior to dosing on Day 1

7. Subject is otherwise in good general health in the judgment of the Investigator as determined from the physical and oral examination findings.

8. Subject is committed to getting help for their opioid dependence, in the judgment of the Investigator.

9. Subject has at least 1 verified contact.

Exclusion Criteria:

1. Inability to meet study participation requirements, including a stay of up to 2 nights in the clinic

2. Positive buprenorphine or methadone result on urine drug screen at Screening or Baseline

3. Concurrent Diagnostic and Statistical Manual of Mental Disorders - 5th edition diagnosis of substance use disorder (excluding opioids and tobacco)

4. Prolonged QT interval by medical history, family history, or current electrocardiogram (ECG) finding

5. History of clinically significant hepatic impairment as determined by the Investigator.

6. Use of any medication, nutraceutical or herbal product with CYP3A4 inhibition or induction properties within the past 30 days. This exclusion also extends to grapefruit juice and grapefruit juice-containing products as well as St. John's wort and St. John's wort-containing products (prescription or nonprescription drugs, vitamins, minerals, or dietary/herbal supplements).

7. Use of an investigational drug or device within the last 30 days

8. History of hypersensitivity, allergy, or intolerance to buprenorphine or naloxone

9. Increased suicidal risk, as determined by meeting any of the following:

• History of suicidal ideation = 3 months prior to Baseline with a score of 4 (intent to act) or 5 (specific plan and intent) on the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

• History of suicidal behavior =1 year prior to Baseline (actual attempt, interrupted attempt, aborted attempt and/or preparatory acts/behavior) on the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

10. Lack of motivation or a pattern of prior poor response to treatment, as judged by the investigator

11. A history or current evidence of any clinically significant disorder or any other condition which in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results

Related Conditions & MeSH terms

• Opioid Dependence

Intervention

Drug:
• BEMA Buprenorphine NX
Buprenorphine with naloxone
• Buprenorphine
Buprenorphine

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
BioDelivery Sciences International

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in COWS total score for BEMA Buprenorphine NX vs BEMA Buprenorphine NX Control	To determine if induction of opioid dependent subjects with BEMA Buprenorphine NX results in more opioid withdrawal symptoms than induction with BEMA Buprenorphine NX Control	At 12 hours post inital dose